Authors' Contributions
B. Martorell, P.
ADVERSE EVENTS, DISEASE, ADENOCARCINOMA OF THE PANCREAS
Study concepts and design were carried out by Y. Sánchez, Y. Saumell, A. R. Valls, and P. P. Guerra. Literature research was carried out by Y. Sánchez, Y. Saumell, A. R. Valls, and P. P. Guerra. Clinical data collection was carried out by Y. Sánchez, M. L. Concepción, Y. Amador, A. Piriz, R. Rabassa, A. Leyva, O. Arguelles, L. Leblanch, S. Moret, G. Rivero, A. L. Vasallo, and B. Martorell. Data analysis was carried out by Y. Sánchez, Y. Saumell, and L. Sánchez. Statistical analyses were carried out by L. Sánchez and Y. Saumell. Manuscript preparation was carried out by Y. Saumell. Manuscript editing was carried out by all authors. All authors revised and approved the final manuscript.Distribution of patients evaluated in the study.The Kaplan-Meier curves for overall survival in first-line treatment patients and according to disease status at inclusion. SD: standard deviation; CI: confidence interval.The Kaplan-Meier curves for overall survival in treatment patients with 8 or more doses of nimotuzumab and according to disease status at inclusion. SD: standard deviation; CI: confidence interval.The Kaplan-Meier curves for progression-free survival in first-line treatment patients and according to disease status at inclusion. SD: standard deviation; CI: confidence interval.Distribution of patients according to demographic and clinical variables.SD: standard deviation; QR: quartile range.General information on adverse events.
List of treatment-related adverse events according to CTCAE
Clinical response for the first-line treatment stratum.
Summary of the main results of clinical trials with anti-EGFR+chemotherapy as first-line treatment in patients with locally advanced or metastatic adenocarcinoma of the pancreas.CI: confidence interval; HR: hazard ratio; N/A: not available; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; Gem: gemcitabine; LGCF: leucovorin, gemcitabine, cisplatin, and 5FU.